After-Hours Stock Movers 04/28: (RRD) (GOOGL) (WW) Higher; (IRBR) (F) (FEYE) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Call Buying Activity in FireEye (FEYE) Targets Upside in Shares Amid M&A Chatter -Susquehanna
April 30, 2020 2:58 PM EDTSusquehanna options strategist Alison Edwards notes call buying activity in FireEye (NASDAQ: FEYE), as an opening investor in FireEye bought 10k May 11 Calls for $0.84 up to $1.00, untied in small lots throughout the morning. This investor opens upside exposure through mid-May, breaking even on a... More
Chimerix (CMRX) Begins Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19
April 29, 2020 7:17 AM EDTChimerix (NASDAQ: CMRX) today announced the Companys initiation of a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI).
DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties, including the potential to address underlying causes of coagulation disorders with substantially reduced risk of bleeding complications compared to commercially available forms of heparin.1
Given the severity of the COVID-19 pandemic, we have evaluated many potential targets to address the clinical manifestations associated with severe COVID-19,said Joseph Lasky, M.D., Professor of Medicine, Pulmonary and... More

